Head-To-Head Analysis: BioHarvest Sciences (NASDAQ:BHST) & CureVac (NASDAQ:CVAC)

CureVac (NASDAQ:CVAC) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, analyst recommendations, profitability, earnings and risk.

Valuation and Earnings

This table compares CureVac and BioHarvest Sciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$543.28 million	1.21	-$281.58 million	$0.55	5.35
BioHarvest Sciences	$22.43 million	4.75	-$12.56 million	($1.25)	-5.18

BioHarvest Sciences has lower revenue, but higher earnings than CureVac. BioHarvest Sciences is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

17.3% of CureVac shares are held by institutional investors. 2.2% of CureVac shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares CureVac and BioHarvest Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CureVac	20.72%	21.98%	15.72%
BioHarvest Sciences	-76.65%	N/A	-85.16%

Analyst Ratings

This is a breakdown of current ratings for CureVac and BioHarvest Sciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	0	3	1	0	2.25
BioHarvest Sciences	0	0	2	0	3.00

CureVac presently has a consensus price target of $10.00, indicating a potential upside of 239.56%. BioHarvest Sciences has a consensus price target of $13.00, indicating a potential upside of 100.62%. Given CureVac’s higher possible upside, equities research analysts clearly believe CureVac is more favorable than BioHarvest Sciences.

Risk and Volatility

CureVac has a beta of 2.53, meaning that its share price is 153% more volatile than the S&P 500. Comparatively, BioHarvest Sciences has a beta of 2.27, meaning that its share price is 127% more volatile than the S&P 500.

Summary

CureVac beats BioHarvest Sciences on 10 of the 14 factors compared between the two stocks.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

About BioHarvest Sciences

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.